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19th CardioVascular Summit: TCTAP 2014with a higher risk of bleeding have limited its widespread use. As the rates of early
stent thrombosis are higher especially in the early stages of STEMI, the use of a more
potent DAPT regimen in the initial period could potentially confer the most beneﬁt.
We therefore sought to evaluate the safety and efﬁcacy of a hybrid DAPT regimen
(involving a switch of prasugrel to clopidogrel at 1 month post MI) in STEMI patients
and report on the clinical outcomes.
Methods: From January to August 2012, 141 STEMI patients (94% male, mean age
54 + 9.2 years) were preloaded with 60 mg of prasugrel and 300 mg of aspirin in the
emergency room of our institution prior to PPCI. Patients aged > 75 years, body
weight < 60 Kg and those with previous history of stroke were excluded.
Upon hospital discharge, patients received maintenance doses of 10 mg of prasugrel
and 100 mg of aspirin for the ﬁrst 30 days. At 30 days post MI, prasugrel was stopped
and patients were loaded with 300 mg of clopidogrel followed by 75 mg as mainte-
nance dose (for the remaining 11 months in conjuction with aspirin). The primary
efﬁcacy end point was a composite of death from cardiovascular causes, nonfatal MI,
or nonfatal stroke at 1 year follow-up. The key safety end point was Thrombolysis in
Myocardial Infarction (TIMI) major bleeding at 1 year follow-up.
Results: PPCI was performed predominantly via the radial approach (86%) with
Clexane used as procedural anti-coagulant in 60% of patients (40% received heparin).
Glycoprotein IIb/IIIa inhibitors were administered in 82% of patients with the majority
(64%) receiving drug eluting stent implantation during PPCI.
The primary end point occurred in 6 patients (4.3%) with 4 events (2.8%) occurring
within the ﬁrst 30 days of MI. Death from cardiovascular causes occurred in 3 patients
(2.1%). Non-fatal MI occurred in 2 patients (1.4%) with 1 patient (0.7%) developing a
non-fatal stroke. Stent thrombosis occurred in 3 patients (2.1%) patients with 1 case of
probable stent thrombosis (0.7%) occurring within 30 days of MI.
Bleeding events were observed in 10 patients (7%) with TIMI major bleeding
episode occurring in 3 patients (2.1%). There was 1 bleeding episode occurring in the
setting of coronary artery bypass surgery.
Conclusion: Our preliminary experience showed that a hybrid DAPT regimen in a
selected group of STEMI patients is feasible, efﬁcacious and safe. The long term
clinical outcomes were good with a low incidence of ischaemic and bleeding events.
TCTAP A-031
Platelet Function Test and Bleeding Risk in Patients with Coronary Artery
Disease: A Case-control Study
Ho Fai Daniel Fong
Princess Margaret Hospital, HK, Hong Kong, China
Background: Management of coronary heart disease remains a challenge even with
modern advances. New anti-platelet agents which reduce thromboembolic events in
patients with coronary heart disease were introduced. However, there are concerns about
an increased in bleeding risk for patients taking these new anti-platelet agents. Platelet
function test, such as VerifyNow, claimed to be able to predict bleeding risk. However,
the evidence was limited, especially among the Asian population. This study aimed to
evaluate the use ofVerifyNow to assess bleeding risk. Subjectswith low residual platelet
reactivity, i.e. low PRU value, were hypothesized to have an increased bleeding risk.
Methods: This was a case control study performed in the Princess Margaret Hospital of
Hong Kong. A total of 120 subjects who were taking a P2Y12 inhibitor and had a
VerifyNow test were recruited. The cases were deﬁned as subjects with a PRU value of
less than or equal to 95, a threshold for increased bleeding risk as recommended by
Western studies. The controls were age matched to the cases. The primary outcome was
the increase in bleeding risk associated with a low PRU value at 30 days. The secondary
outcomewas the increase in bleeding risk associatedwith a lowPRUvalue at 1 year. The
use of the percentage of platelet inhibition was also evaluated as a secondary outcome.
Multivariable logistic regression was used to obtain the odds ratio of the low PRUgroup.
Results: Bleeding events occurred more frequently in the low PRU group. At 30 days,
31.7% of subjects among the case had a bleeding event while 43.3% of the cases had a
bleeding event at 1 year. The majority of these bleeding events were minor bleeding,
such as easy bruising. After adjusting for confounders, there was no statistically
signiﬁcant increase in bleeding risk among those in the low PRU group at 30 days or 1
year. Subjects with a high percentage of platelet inhibition (>50%) was also not
associated with a statistically signiﬁcant increase in bleeding risk.
Conclusion: A low PRU value was not associated with an increased bleeding risk at 30
days. Thus the VerifyNow test was not shown to be useful in assessing the bleeding risk of
patients in anAsian population, contrary to theﬁndings fromWestern literature.A possible
explanation was that the VerifyNow threshold for predicting bleeding might be higher
among the Asian population. The deﬁnition for low residual platelet reactivity might be
different in our locality. A larger sample size might also be needed. Further studies are
needed to evaluate whether a different cut off is more optimal for the Asian population.
TCTAP A-032
Comparison of Platelet Reactivity and Clinical Outcomes in Patients Treated
with Clopidogrel and Coronary Intervention
Sang Yeub Lee, Ju-Hee Lee, Sang Min Kim, Jang-Whan Bae, Kyung-Kuk Whang,
Dong-oon Kim, Myeong-Chan Cho
Chungbuk National University Hospital, Cheongju, Korea (Republic of)
Background: Platelets are associated with vascular occlusive event. High on-clopi-
dogrel platelet reactivity (HPR) is associated with recurrent thrombotic events after
percutaneous coronary intervention (PCI). We evaluated platelet reactivity measured
by the VerifyNow P2Y12 assay and clinical outcomes in patients receiving clopi-
dogrel and PCI of real world practice.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORAMethods: We recruited A total of 878 consecutive clopidogrel-treated patients un-
dergoing emergent or elective PCI. The main outcome measures were cardiovascular
(CV) death, deﬁnite/probable stent thrombosis (ST), nonfatal myocardial infarction
(MI), coronary revascularization and a composite end point of ischemic events. We
assessed Platelet reactivity 12 hours later by measuring P2Y12 reactivity unit (PRU)
with VerifyNow P2Y12 assay (Accumetrics, San Diego, California). High platelet
reactivity (HPR) was deﬁned as PRU value  240 or 280.
Results: In total, 877 consecutive patients were enrolled. Patients with HPR were 454
(Male, 284). In all patients, coronary stent was implanted. All patients received clo-
pidogrel pretreatment (300mg loading dose), received a maintenance dose of 75 mg
daily. The composite end points of the study at follow-up of 12 months were CV
death, nonfatal MI, and coronary revascularization. At a 12-month follow-up, we
found 85 ischemic events (26 CV deaths [3.4%], 11 nonfatal MIs [1.4%]) and 56
target-vessel revascularizations (7.1%). The composite event rate of patients with HPR
(PRU > 240) was signiﬁcantly higher (7.5% vs 4.3% (p ¼ 0.047)) than the patient
with normal value. In survival analysis, there was no signiﬁcant difference between
patient with HPR (PRU > 240) and normal reactivity. But between patient with HPR
(PRU > 280) and normal reactivity, the survival rate free from the primary end point
was signiﬁcantly lower in patients with HPR (p ¼ 0.014, Generalized Wilcoxon test).
Conclusion: High on-clopidogrel platelet reactivity tested by VerifyNow predict
coronary adverse event in patients after PCI. In Korean, we seem to have to raise the
optimal cutoff value of PRU to predict future coronary event.
TCTAP A-033
Reappraisal of Pharmacodynamic Effect of Adjunctive Cilostazol and High-dos
Clopidogrel in East Asian ACS Patients
Young-Hoon Jeong, Yongwhi Park, Jin Sin Koh, Jin-Yong Hwang
Gyeongsang National, Jinju, Korea (Republic of)
Background: Compared with Westerners, East Asians have shown different thera-
peutic level of platelet reactivity (PR) regarding post-PCI ischemic and bleeding
events. We also reported different therapeutic level for East Asians (35% < 20 mM
ADP-PR < 70%). We reappraised the pharmacodynamic effect of adjunctive cil-
ostazol and high-dose clopidogrel in East Asians based on this criteria.
Methods: PCI-treated ACS patients were assigned to either clopidogrel 150 mg/d
(DOUBLE; n¼139) or cilostazol 100 mg bid + clopidogrel 75 mg/d (TRIPLE; n¼136)
on top of aspirin. PR was measured at least 30-day follow-up with light transmittance
aggregometry. Primary endpoint was the prevalence of HPR at follow-up.
Results: DOUBLE and TRIPLE together showed low prevalences of HPR (9.4% and
2.2%, respectively). Although the level of PR in TRIPLE increased according to the
number of CYP2C19 loss-of-function (LoF) allele (p¼0.015), HPR risk was almost
overcome irrespective of CYP2C19 phenotype (p¼0.633). The level of PR and HPR
risk in DOUBLE increased proportionally depending on CYP2C19 phenotype
(p<0.001 and p¼0.006, respectively). In multivariate analysis, carriage of 2
CYP2C19 LoF alleles only increased HPR risk by 8.5-fold in DOUBLE.
Conclusion: Our results support clinical usefulness of TRIPLE in East Asians based
on pharmacodynamic data. Clinical efﬁcacy and safety of more potent P2Y12 in-
hibitor, prasugrel and ticagrelor, must be reevaluated separately in this unique race.TCTAP A-034
Observational Studies of Bleeding and Thrombotic Events in Acute Coronary
Syndrome Patients Between Different Metabolizer of Clopidogrel
Wen Duo Zhang, Fu Sui Ji
Beijing Hospital, Beijing, China
Background: Compared with CYP2C19*1 carriers，CYP2C19*2,*3 carriers have
a higher risk of stent thrombosis in clopidogrel-treated patients. ThereforeL/Antiplatelet Agents and Anticoagulants S9
